Session One: Basal Insulins: Still Innovating After All These Years

  • Home / Session One: Basal Insulins: Still Innovating After All These Years

Session One: Basal Insulins: Still Innovating After All These Years

This Sanofi sponsored symposium, titled ‘Evolving Standards and Innovation in Diabetes Care’, took place on 11th September 2017, as part of the 53rd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Lisbon, Portugal.

Symposium Chair: Elizabeth Seaquist1
Session Chair: Robert Ritzel2
Speakers: Jeremy Pettus,3 Kamlesh Khunti4

1. University of Minnesota, Minneapolis, Minnesota, USA
2. Klinikum Schwabing, Munich, Germany
3. University of California San Diego, San Diego, California, USA
4. University of Leicester, Leicester, UK

Disclosure: Elizabeth Seaquist has been a consultant, advisor, or received honoraria from the American Board of Internal Medicine, American Diabetes Association, Eli Lilly, Endocrine Society, Locemia, Novo Nordisk, and Zucera. She has received research support from Eli Lilly, Juvenile Diabetes Research Foundation and the National Institutes of Health, and has received travel/speaker reimbursement from the American Board of Internal Medicine, American Diabetes Association, Eli Lilly, Endocrine Society, National Institutes of Health, and Novo Nordisk. Robert Ritzel has been a consultant for Merck Sharp & Dohme, Novo Nordisk, Sanofi, and Servier. He has also undertaken speaking engagements for AstraZeneca, Berlin-Chemie, Eli Lilly, Merck Sharp & Dohme, Novartis, Novo Nordisk, and Sanofi. Jeremy Pettus has been a consultant for Sanofi, Novo Nordisk, and Mannkind. Kamlesh Khunti has been a consultant and undertaken speaking engagements for Amgen, Eli Lilly, Merck Sharp & Dohme, Novartis, Novo Nordisk, Sanofi, and Servier. He has provided research support with investigator-initiated trials for Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Novartis, Novo Nordisk, Pfizer, and Sanofi.
Acknowledgements: Writing assistance was provided by Dr Lisa Michel, Ashfield Healthcare Communications Ltd., London, UK.
Support: The publication of this article was funded by Sanofi. The views and opinions expressed are those of the speakers and not necessarily of Sanofi.
Citation: EMJ Diabet. 2017;5[1]:38-45.

Meeting Summary

Therapeutic basal insulin has evolved considerably over the past 90 years. A series of landmark innovations has led to the availability of therapies that closely mimic the physiological effects of endogenous insulin and serve as an invaluable addition to the treatment armamentarium for diabetes. Advances in basal insulin have led to the development of the newer basal insulin analogues, namely insulin degludec and insulin glargine 300 U/mL (Gla-300). The desirable pharmacokinetic (PK) and pharmacodynamic (PD) properties of these basal insulins, such as a prolonged duration of action (≥24 hours), may translate into a number of clinical benefits for the patient e.g., a simple, once-daily injection schedule and flexible injection timings.

The technologies supporting patients with diabetes have also evolved considerably in recent years. Continuous glucose monitoring (CGM) can provide insights into some of the challenges faced by patients with diabetes, e.g., glycaemic excursions and the impact of injection time, and may become an alternative to the current gold standard glycated haemoglobin (HbA1c). Real-world evidence is also providing fresh perspectives on the effectiveness of basal insulins in clinical practice. Today, innovative methods for real-world evidence collection, analysis, and interpretation are helping to generate robust datasets with external validity. Taken together, these innovative approaches are generating an integrated evidence base that is improving our understanding of how basal insulin therapy can be optimised for the benefit of our patients with diabetes.

This article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

The post Session One: Basal Insulins: Still Innovating After All These Years appeared first on European Medical Journal.

About Post Author

Medical CPD & News

The Digitalis CPD trawler searches the web for all the latest news and journals.

Privacy Preference Center

Close your account?

Your account will be closed and all data will be permanently deleted and cannot be recovered. Are you sure?

Are you sure?

By disagreeing you will no longer have access to our site and will be logged out.